Date: 2013-06-26
Type of information: Credit line
Company: Kiadis Pharma (The Netherlands)
Investors: Agentschap NL (The Netherlands)
Amount: up to €3 million
Funding type: credit line
Planned used: The funds will be used to support the Phase II clinical development of Kiadis Pharma’s lead pipeline product, ATIR™.
Others: * On June 26, 2013, Kiadis Pharma,a clinical stage biopharmaceutical company developing treatments for blood cancers, has announced that it will receive an innovation credit of up to €3 million from AgentschapNL, a division of the Dutch Ministry of Economic Affairs, to support the Phase II clinical development of Kiadis Pharma’s lead pipeline product, ATIR™.
Kiadis Pharma is currently conducting a Phase II international multi-center study with ATIR™, its cell based product for blood cancers, in order to confirm and extend previous Phase I/II results. This cell based medicinal product has beed designe to enable stem cell transplantations using partially mismatched (haploidentical) family members as donors for patients suffering from blood cancer who lack a suitable standard of care matched donor. Stem cell transplantation is the only potentially curative treatment for many patients but a matching donor is available for only half of the patients in need. ATIR™ thus has the potential to address this unmet need and to make stem cell transplantations available for all patients worldwide.
ATIR™ has been granted Orphan Drug Designation both in the EU and the USA.
Therapeutic area: Cancer - Oncology
